Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Calliditas enrols first patient in Phase III study of Nefecon

Immunostaining for IgA in a patient with Henoch-Schönlein nephritis. Credit: Lazarus Karamadoukis, LinmarieLudeman and Anthony J Williams.

  • Calliditas Therapeutics

Go Top